Syncona portfolio company Freeline prices US IPO
7th Aug 2020 08:17
(Sharecast News) - Healthcare investment company Syncona announced on Friday that its portfolio company Freeline Therapeutics has priced its initial public offering in the United States.
Read moreSyncona's Freeline files IPO registration document
20th Jul 2020 07:22
(Sharecast News) - Healthcare investor Syncona said its portfolio company Freeline Therapeutics has filed a registration statement with the US Securities and Exchange Commission for a proposed initial public offering (IPO).
Read moreSyncona revalues holding in Freeline after expanded series C
30th Jun 2020 08:26
(Sharecast News) - Healthcare investment and development company Syncona announced on Tuesday that Freeline Therapeutics - a biotechnology company focussed on developing curative gene therapies for chronic systemic diseases - has raised a further $80m (£65.09m) from specialist global institutional investors in an expanded series C round.
Read moreSyncona asset values fall after Autolus shares plunge
11th Jun 2020 08:32
(Sharecast News) - Syncona reported a 13% fall in net asset value as the value of its life sciences division dropped by a quarter in its most recent financial year.
Read moreSyncona portfolio firm Achilles doses first patient in T cell therapy trial
29th May 2020 08:12
(Sharecast News) - Syncona announced on Friday that its portfolio company, Achilles Therapeutics, has dosed the first patient in a phase 1 and 2 clinical study of its clonal neoantigen T cell (cNeT) therapy, in patients with recurrent or metastatic malignant melanoma.
Read moreSyncona announces expanded commitment to SwanBio
23rd Apr 2020 08:54
(Sharecast News) - Syncona announced a new $51m (?41.39m) commitment in an expanded $77m series A round of financing by SwanBio Therapeutics on Thursday.
Read moreDirector dealings: Syncona chair acquires shares
31st Mar 2020 16:20
(Sharecast News) - Syncona revealed on Tuesday that chairperson Melanie Gee had acquired 26,500 ordinary shares in the FTSE 250-listed life sciences investor.
Read moreSyncona flags delays to clinical programmes amid pandemic
23rd Mar 2020 09:36
(Sharecast News) - Syncona updated the market on its trading amid the Covid-19 coronavirus pandemic on Monday, reporting that since the start of the outbreak, it had taken measures to protect its employees, primarily centred around remote working, to help ensure it could continue to operate with as minimal disruption as possible.
Read moreMonday broker round-up
24th Feb 2020 12:28
(Sharecast News) - Rentokil: Jefferies upgrades to buy with a target price of 620p.
Read moreSyncona pleased at end of 'productive' quarter
4th Feb 2020 11:33
(Sharecast News) - Healthcare investment company Syncona updated the market on the quarter ended 31 December on Tuesday, reporting that its had expanded, invested in and advanced its portfolio in the period.
Read moreSyncona puts $15m into Autolus US offering
23rd Jan 2020 08:14
(Sharecast News) - Healthcare investment company Syncona announced on Thursday that its portfolio company, Autolus Therapeutics, had confirmed the pricing of its underwritten public offering in the United States.
Read moreSyncona commits $80m to Freeline
19th Dec 2019 07:53
(Sharecast News) - Healthcare company Syncona said it had made an $80m (£61.1m) funding commitment to biotech company Freeline.
Read moreSyncona upbeat on latest data from Autolus Therapeutics
9th Dec 2019 09:32
(Sharecast News) - Syncona shares were just above the waterline on Monday morning, after two updates from its portfolio company Autolus Therapeutics, in which it announced new data at the American Society of Hematology (ASH) annual meeting in Orlando, Florida.
Read moreSyncona sees negative returns as it continues to invest in portfolio firms
21st Nov 2019 08:34
(Sharecast News) - Healthcare investment company Syncona reported net assets of £1.37bn in its interim results on Thursday, down from £1.46bn at the end of the last financial year.
Read moreSyncona invests ?83.1m in Gyroscope and Achilles
3rd Sep 2019 07:58
(Sharecast News) - Syncona on Tuesday confirmed investments of £48.0m in retinal gene therapy group Gyroscope Therapeutic and £35.1m in cancer immunotherapies developer Achilles Therapeutics.
Read more